Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.37)
# 3,368
Out of 4,868 analysts
36
Total ratings
44.44%
Success rate
-11.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Equal-Weight | $150 → $135 | $128.12 | +5.37% | 3 | Jun 3, 2025 | |
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.38 | +1,199.04% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.83 | +239.75% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $22.81 | +44.67% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $3.03 | +164.03% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $21.86 | +128.73% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $40.74 | -28.82% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.41 | +102.43% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $11.62 | +166.78% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $46.44 | +29.20% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.46 | +242.47% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.44 | +177.78% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.47 | +636.28% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.14 | +1,040.35% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.16 | +76.55% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $7.48 | +1,236.90% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.95 | +925.64% | 1 | May 14, 2024 |
Blueprint Medicines
Jun 3, 2025
Downgrades: Equal-Weight
Price Target: $150 → $135
Current: $128.12
Upside: +5.37%
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.38
Upside: +1,199.04%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.83
Upside: +239.75%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $22.81
Upside: +44.67%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.03
Upside: +164.03%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $21.86
Upside: +128.73%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $40.74
Upside: -28.82%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.41
Upside: +102.43%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $11.62
Upside: +166.78%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $46.44
Upside: +29.20%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.46
Upside: +242.47%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.44
Upside: +177.78%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.47
Upside: +636.28%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.14
Upside: +1,040.35%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.16
Upside: +76.55%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $7.48
Upside: +1,236.90%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.95
Upside: +925.64%